Advertisement

Epidemiology and Clinical Features

  • Nikolaos Tsoukalas
  • Sarah RudmanEmail author
Chapter
Part of the Clinicians’ Guides to Radionuclide Hybrid Imaging book series (CGRHI)

Abstract

Prostate cancer is the most common non-cutaneous malignancy in Westernised countries with a lifetime risk of one in seven men [1] and a global incidence of more than one million new cases each year (Figs. 1.1 and 1.2) [2]. In 2012, 417,000 cases were diagnosed in Europe with the highest incidence in Northern and Western Europe in countries such as Norway (129/100,000) and lowest in Southeastern Europe in countries such as Albania [3]. The UK incidence places it 17th overall with an age-standardised rate of 104.7 cases/100,000 (Figs. 1.3 and 1.4). It is thought that widespread differences in screening practices, prostate-specific antigen (PSA) testing, and digital rectal examination (DRE) may explain the variation in country to country incidence.

References

  1. 1.
    Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9–29.CrossRefPubMedGoogle Scholar
  2. 2.
    Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide: IARC CancerBase No. 11 [Internet]. Lyon: International Agency for Research on Cancer; 2013. http://globocan.iarc.fr. Accessed December 2013.
  3. 3.
    Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D, Bray F. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49:1374–403.CrossRefPubMedGoogle Scholar
  4. 4.
  5. 5.
    De Angelis R, Sant M, Coleman MP, Francisci S, Baili P, Pierannunzio D, Trama A, Visser O, Brenner H, Ardanaz E, Bielska-Lasota M, Engholm G, Nennecke A, Siesling S, Berrino F, Capocaccia R, EUROCARE-5 Working Group. Cancer survival in Europe 1999–2007 by country and age: results of EUROCARE—5-a population-based study. Lancet Oncol. 2014;15(1):23–34.CrossRefPubMedGoogle Scholar
  6. 6.
    Van der Kwast TH, Roobol MJ. Defining the threshold for significant versus insignificant prostate cancer. Nat Rev Urol. 2013;10(8):473–82.CrossRefPubMedGoogle Scholar
  7. 7.
    Cohen JH, Schoenbach VJ, Kaufman JS, Talcott JA, Schenck AP, Peacock S, Symons M, Amamoo MA, Carpenter WR, Godley PA. Racial differences in clinical progression among Medicare recipients after treatment for localized prostate cancer (United States). Cancer Causes Control. 2006;17(6):803–11.CrossRefPubMedGoogle Scholar
  8. 8.
    Godley PA, Schenck AP, Amamoo MA, Schoenbach VJ, Peacock S, Manning M, Symons M, Talcott JA. Racial differences in mortality among Medicare recipients after treatment for localized prostate cancer. J Natl Cancer Inst. 2003;95(22):1702–10.CrossRefPubMedGoogle Scholar
  9. 9.
    Powell IJ. Epidemiology and pathophysiology of prostate cancer in African-American men. J Urol. 2007;177(2):444–9.CrossRefPubMedGoogle Scholar
  10. 10.
    Williams H, Powell IJ. Epidemiology, pathology, and genetics of prostate cancer among African Americans compared with other ethnicities. Methods Mol Biol. 2009;472:439–53.CrossRefPubMedGoogle Scholar
  11. 11.
    Haas GP, Sakr WA. Epidemiology of prostate cancer. CA Cancer J Clin. 1997;47(5):273–87.CrossRefPubMedGoogle Scholar
  12. 12.
    Kote-Jarai Z, Leongamornlert D, Saunders E, Tymrakiewicz M, Castro E, Mahmud N, Guy M, Edwards S, O’Brien L, Sawyer E, Hall A, Wilkinson R, Dadaev T, Goh C, Easton D, Collaborators UKGPCS, Goldgar D, Eeles R. BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients. Br J Cancer. 2011;105(8):1230–4.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Sutcliffe S, Platz EA. Inflammation and prostate cancer: a focus on infections. Curr Urol Rep. 2008;9(3):243–9.CrossRefPubMedGoogle Scholar
  14. 14.
    Crowe FL, Key TJ, Appleby PN, Travis RC, Overvad K, Jakobsen MU, Johnsen NF, Tjψnneland A, Linseisen J, Rohrmann S, Boeing H, Pischon T, Trichopoulou A, Lagiou P, Trichopoulos D, Sacerdote C, Palli D, Tumino R, Krogh V, Bueno-de-Mesquita HB, Kiemeney LA, Chirlaque MD, Ardanaz E, Sαnchez MJ, Larraρaga N, Gonzαlez CA, Quirσs JR, Manjer J, Wirfδlt E, Stattin P, Hallmans G, Khaw KT, Bingham S, Ferrari P, Slimani N, Jenab M, Riboli E. Dietary fat intake and risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition. Am J Clin Nutr. 2008;87(5):1405–13.PubMedGoogle Scholar
  15. 15.
    Travis RC, Crowe FL, Allen NE, Appleby PN, Roddam AW, Tjψnneland A, Olsen A, Linseisen J, Kaaks R, Boeing H, Krφger J, Trichopoulou A, Dilis V, Trichopoulos D, Vineis P, Palli D, Tumino R, Sieri S, Bueno-de-Mesquita HB, van Duijnhoven FJ, Chirlaque MD, Barricarte A, Larraρaga N, Gonzαlez CA, Argόelles MV, Sαnchez MJ, Stattin P, Hallmans G, Khaw KT, Bingham S, Rinaldi S, Slimani N, Jenab M, Riboli E, Key TJ. Serum vitamin D and risk of prostate cancer in a case-control analysis nested within the European Prospective Investigation into Cancer and Nutrition (EPIC). Am J Epidemiol. 2009;169(10):1223–32.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Horwich A, Parker C, de Reijke T, Kataja V, ESMO Guidelines Working Group. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl 6):vi106–14.CrossRefPubMedGoogle Scholar
  17. 17.
    Epstein JI, Allsbrook Jr WC, Amin MB, Egevad LL, ISUP Grading Committee. The 2005 international society of urological pathology (ISUP) consensus 22. Conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol. 2005;29(9):1228–42.CrossRefPubMedGoogle Scholar
  18. 18.
    Hara R, Jo Y, Fujii T, Kondo N, Yokoyoma T, Miyaji Y, Nagai A. Optimal approach for prostate cancer detection as initial biopsy: prospective randomized study comparing transperineal versus transrectal systematic 12-core biopsy. Urology. 2008;71(2):191–5.CrossRefPubMedGoogle Scholar
  19. 19.
    Takenaka A, Hara R, Ishimura T, Fujii T, Jo Y, Nagai A, Fujisawa M. A prospective randomized comparison of diagnostic efficacy between transperineal and transrectal 12-core prostate biopsy. Prostate Cancer Prostatic Dis. 2008;11(2):134–8.CrossRefPubMedGoogle Scholar
  20. 20.
    Oesterling JE. Using prostate-specific antigen to eliminate unnecessary diagnostic tests: significant worldwide economic implications. Urology. 1995;46(3 Suppl A):26–33.CrossRefPubMedGoogle Scholar
  21. 21.
    Levran Z, Gonzalez JA, Diokno AC, Jafri SZ, Steinert BW. Are pelvic computed tomography, bone scan and pelvic lymphadenectomy necessary in the staging of prostatic cancer? Br J Urol. 1995;75(6):778–81.CrossRefPubMedGoogle Scholar
  22. 22.
    Sobin LH, Gospodariwicz M, Wittekind C, editors. TNM classification of malignant tumors. In: UICC International Union against cancer. 7 edn. Hoboken: Wiley-Blackwell; 2009. P. 243–48. http://www.uicc.org/tnm/.
  23. 23.
    D’Amico AV, Moul J, Carroll PR, Sun L, Lubeck D, Chen MH. Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. J Clin Oncol. 2003;21(11):2163–72.CrossRefPubMedGoogle Scholar
  24. 24.
    D’Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, Tomaszewski JE, Renshaw AA, Kaplan I, Beard CJ, Wein A. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280(11):969–74.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  1. 1.Department of OncologyGuy’s & St Thomas’ NHS Foundation TrustLondonUK

Personalised recommendations